- Home
- KRC vs BLLN Comparison
KRC vs BLLN Comparison
Compare KRC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | BLLN |
|---|---|---|
| Founded | 1947 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | KRC | BLLN |
|---|---|---|
| Price | $28.23 | $80.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $37.36 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 2.1M | 281.7K |
| Earning Date | 04-27-2026 | 03-04-2026 |
| Dividend Yield | ★ 7.79% | N/A |
| EPS Growth | ★ 31.07 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $1,112,667,000.00 | N/A |
| Revenue This Year | N/A | $45.96 |
| Revenue Next Year | $2.31 | $30.11 |
| P/E Ratio | $11.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.36 | $61.96 |
| 52 Week High | $45.03 | $138.70 |
Technical Indicators
Market Signals| Indicator | KRC | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 51.76 |
| Support Level | $27.63 | $80.39 |
| Resistance Level | $43.30 | $83.20 |
| Average True Range (ATR) | 0.91 | 6.77 |
| MACD | 0.14 | 1.35 |
| Stochastic Oscillator | 41.93 | 49.68 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About BLLN BillionToOne Inc.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.